The aim of this biomedical trial was to clarify the physiological role of procalcitonin (PCT) in renal parenchyma apoptosis and fi brosis caused by acute childhood pyelonephritis. This prospective study enrolled 183 children. All children were treated with bi-therapy according to the French consensus on acute pyelonephritis treatment dated November 16, 1990: intravascular administration of ceftriaxone 50 mg/kg/day and netromicine 7 mg/kg/day during the fi rst 48 hours, followed by specifi c antibiotherapy suited to antibiogram. On admission, PCT, C-reactive protein, and phospholipase A2 were quantifi ed in serum. Scintigraphy monitoring with 99m Tc-DMSA was performed on day 4 and 9 months later, in the presence of persistent abnormalities. On day 4, 78% presented renal parenchyma alterations and 30% renal fi brosis 9 months after admission. Paradoxically, PCT level was signifi cantly lower in the presence of renal fi brosis due to cell apoptosis (4.19 vs 7.59 µgL -1 ). A signifi cant increase in PCT indicated favorable progress (recovery 7.55 vs aggravation 3.34) and no difference between recovery and improvement. This result suggests the protective effect of PCT against apoptosis by nitric oxide down-regulation.
Background
Researchers generally agree that increased procalcitonin (PCT) synthesis is detrimental to the host because a high concentration of this calcitonine precursor refl ects the severity of sepsis and is predictive of mortality (Bossink et al 1999) . Procalcitonin, a 116 amino acid peptide, is produced physiologically by thyroid C-cells and cleaved by specifi c protease. This prohormone is found at low concentration (Ͻ0.1 ng/mL) in healthy subjects and at high concentration in critically ill patients with a particular infection or shock. Although the role and production site of the PCT are unclear, this peptide induced by tumor necrosis factor alpha (TNF-α) is currently considered to be an effective infl ammatory marker used to monitor septic shock, pancreatic necrosis, or burn injuries (Venet et al 2002) .
Recently, our research has focused on how PCT is implicated in acute childhood pyelonephritis (AP), followed in 30% of cases by renal fi brosis (RF) leading to chronic sequelae (such arterial hypertension gravidic toxemy). Renal fi brosis results from functional parenchyma disorder consecutive to renal cell apotosis, usually mediated by lipopolysaccharide (LPS)-induced TNF-α production. During the infection of the renal parenchyma, the bacterial LPS of the membranes induces the release of TNF, interleukin-1 (IL1), and IL6 (Oberhoffer et al 1999) .
Pro-infl ammatory TNF-α activates nitric oxide (NO) release, which is catalyzed by nitric oxide synthase (NOS) in the presence of Ca 2+ /calmodulin. Thus intracellular calcium concentration is crucial for Ca 2+ /calmodulin complex formation and NOS activation-inducing apoptosis (Arena et al 2002) .
In fact, cell viability and apoptosis depends on the spatiotemporal organization of cytosolic Ca ++ leading to transmembrane polarization magnitude (Lang et al 2005) . In this context, the renal scintigraphy using the polar 99m Tc-DMSA complex allows parenchyma exploration and then monitoring of acute and chronic lesions due to membrane adsorption attenuation (Belhadj-Tahar et al 2000) .
The aim of this work is to clarify the physiological role of PCT in AP by monitoring the early and later renal lesions (edema/fi brosis) using 99m Tc-DMSA parenchyma exploration.
Material and methods
This prospective study enrolled 183 children. All subjects exhibited clinical and biological infectious syndrome, with abdominal or lumbar pains and positive urine culture before antibiotherapy administration. All children were treated with bi-therapy according to the French consensus on acute pyelonephritis treatment dated November 16, 1990: intravascular administration of ceftriaxone 50 mg/kg/day and netromicine 7 mg/kg/day during the fi rst 48 hours, followed by specifi c antibiothérapy suited to antibiogram.
On admission C-reactive protein (CRP), phospholipase A 2 , and procalcitonin were measured by the following methods: CRP turbidimetric immunoassay (Olympus diagnostica, GmbH) PLA 2 : fl uometric assay (SFM 25 Kontron Instruments) and PCT: luminescent immunoassay (Brahms diagnostica GmbH). Procalcitonin in serum were quantifi ed as well as CRP and phospholipase A 2 . Scintigraphy monitoring with intravascular 99m Tc-DMSA (CIS Bio International, France) was performed according to MacKenzie protocol (MacKenzie 1996) on day 4 and nine months after admission in the presence of persistent abnormalities.
The scintigraphic parenchyma lesions were classifi ed into 4 categories: absence (stage 0), unique and focal (stage II), multiple but unilateral (stage II), and bilateral (stage III).
Results
At day 4, 78% (107/136) had scintigraphic parenchyma renal alterations and 30% (17/57) presented renal fi brosis at 9th month. On admission, except for CRP, both PLA 2 and PCT were signifi cantly higher in patients with early scintigrahic alteration (PCT: 7.85 vs 2.36 µg/L and PLA 2 : 72.1 vs 29.9 IU/L) (Table1).
Discussion
During the infection of the renal parenchyma, the bacterial LPS of the membranes induces the release of TNF, IL1, and IL6.
These cytokines are capable of evoking fever, infl ammation syndrome, and cell apoptosis followed by fi brosis (Figure 1 ).
In the acute phase, IL1 and IL6 induce hepatic production of CRP and PLA 2 leukocyte release. PLA 2 is directly implied in the infl ammatory process including the prostaglandins production from arachidonic acid in the presence of cyclooxygenase (Diaz 1996) . Whereas, procalcitonin CRP and PLA 2 have weak discriminative power for predictive renal fi brosis regarding to their AUC values below 0.65 (see Figure 1) .
We hypothesized that PCT down-regulates nitric oxide (NO) release produced by NO-Synthase activated by TNF-α pro-infl ammatory cytokine (Figure 2 ). Indeed, PCT was paradoxically signifi cantly lower in the presence of chronic renal fi brosis (4.19 ± 1.03 vs 7.59 ± 3.45 µgL -1 ). We observe a signifi cant PCT increase in the favorable progress (recovery 7.55 ± 4.02 vs aggravation 3.34 ± 1.09) and no difference between recovery and improvement evolution. These results suggest the protective effect of PCT against apoptosis resulting from down-regulation of nitric oxide release catalyzed by NO-synthase (Figure 1 ) and corroborate the previous In vitro observations (Hoffmann et al 2003) . Stage Ͼ 0 44.07 ± 4.26 n = 107 M: 29%; F: 71% 114.60 ± 9.74 n = 100 72.03 ± 7.94 n = 87 7.85 ± 1.93 n = 65
Stage I 37.91 ± 4.47 n = 72 M: 15%; F: 38% 114.60 ± 9.0 n = 66 76.32 ± 13.08 n = 57 6.40 ± 1.99 n = 47
Stage II 48.70 ± 7.30 n = 21 M: 5%; F: 10% 130.14 ± 23.36 n = 21 32.70 ± 6.72 n = 17 7.34 ± 4.66 n = 11
Stage III 33.47 ± 8.79 n = 14 M: 1%; F: 9% 121.07 ± 16.46n = 14 104.65 ± 28.47 n = 13 18.37 ± 9.46 n = 7 9th month Absence 39.86 ± 6.78 n = 40 M: 17%; F: 53% 101.16 ± 12.20 n = 37 61.80 ± 12.22 n = 33 7.59 ± 3.45 n = 24 
Conclusion
Our study shows that PCT plays key role in the renal parenchyma protection against cell apopotosis and fi brosis caused by acute pyelonephritis. this fi nding constitutes a original approach in the comprehension of apoptosis paradigm that causes parenchyma fi brosis.
